Gastro-intestinal stromal tumors: News and comments;Tumeurs stromales du tractus digestif: Actualités 2003

Bulletin du Cancer

Volumn 90, Issue 1, 2003, Pages 69-76

  Ray Coquard, Isabelle ^a   Le Cesne, Axel ^b   Michallet, Véronique ^c   Boukovinas, Ioannis ^b   Ranchere, Dominique ^a   Thiesse, P ^a   Baty, Vincent ^a   Blay, Jean Yves ^d  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CROIX ROUSSE HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Gastrointestinal stromal tumor; Imatinib

Indexed keywords

CD34 ANTIGEN; IMATINIB; STEM CELL FACTOR;

ADVANCED CANCER; ANEMIA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COILED BODY; DIAGNOSTIC PROCEDURE; DIARRHEA; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; LEYDIG CELL; MUTATION; MYALGIA; NAUSEA; ONCOGENE; PANCYTOPENIA; PROGNOSIS; REVIEW; SMOOTH MUSCLE FIBER; STEM CELL; TREATMENT OUTCOME; VOMITING;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL NEOPLASMS; HUMANS; MUTATION; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SOFT TISSUE NEOPLASMS;

EID: 1642464911     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983, 7: 507-19.
2. Sarlomo-Rikala M, Kovatich A, Barusevicious A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998, 11: 728-34.
3. Monihan JM, Carr NJ, Sobin LH. CD34 immunoexpression in stromal tumors of the gastrointestinal tract and in mesenteric fibromatoses. Histopathology 1994, 25: 469-73.
4. Miettinen M, Viroloinen M, Sarlomo-Rikala M. Gastrointestinal stromal tumors: value of CD34 antigen in their identification and separation from the leiomyomas and schwannomas. Am J Surg Pathol 1995, 19: 207-16.
5. Kindblom LG, Remorti HE, Aldenborg F, et al. Gastrointestinal pacemakers cell tumors (Gipact): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Surg Pathol 1998, 152: 1259-69.
6. Miettinen M. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathol 1999, 30: 1213-20.
7. Demetri GD. Targetting c-kit mutations in solid tumors :scientific rational et novel therapeutic options. Sem Oncol 2001; 28 (5 suppl17): 19-26.
8. Bedossa F, Blay JY, Coindre JM, Le Cesne A, Monges G, Berthaud P, et al. Épidémiologie et prise en charge des tumeurs stromales gastrointestinales en France. Journées francophones de pathologie digestive 2003 (soumis).
9. Kindblom LG, Meis-Kindblom J, Bümming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST): a population-based study of 600 cases. Ann Oncol 2002; 5770 (abstract).
10. Emory TS, Sobin LH, Lakes L, et al: Prognosis of gastrointestinal smooth muscle (stromal) tumors. Am J Surg Pathol 1999; 23: 82-7.
11. Hirota S, Isozaki K, Moriyama T, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
12. Moskaluk CA, Tian Q, Marshall CR, et al. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999; 18: 1897-902.
13. Rubin BP, Singer S, Tsao T, et al. KIT activation is a ubiquitus feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-21.
14. Longley BJ, Reguera MJ, Ma Y. Classes of c-kit activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001; 25: 571-6.
15. Linnekin D. Early signaling pathways activated by c-kit in hematopoietic cells. Int J Bioch Cell Biol 1999; 31: 1053-74.
16. Huiszinga W. Kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 347-9.
17. Vliagoftis H, Worobec AS, Metcalf DD. The proto-oncogene c-kit and c-kit ligand in human disease. J Alleg Clin Immunol 1997; 100: 435-40.
18. Andersson J, Sjogren H, Meis-Kindblom, et al. The complexicity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002; 160.
19. Heinrich MC, Corless CL, Blanke C, et al. KIT mutational status predict clinical response to STI-571 in patients with metastatic gastrointestinal stromal tumors. Proc Am Soc Clin Soc 2002, 21 (abstract 6).
20. Maeyama H. Familial gastrointestinal stromal tumor with hypergmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120: 210-5.
21. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41-7.
22. Cooper PN, Quirque P, Hardy GJ, et al. A flow, cytometric, clinical and histological study of stromal neoplasms of the gastrointestinal tract. Am J Surg Pathol 1992; 16: 163-70.
23. Cunnigham RE, Federspiel BH, McCarthy WF, et al. Predicting prognosis of gastrointestinal stromal smooth muscle tumors: role of clinical and histologic evaluation, flow cytometry and image cytometry. Am J Surg Pathol 1993; 17: 588-94.
24. Taniguchi M Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-300.
25. Lasota J, Jazinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 53-60.
26. Seidal T, Edvardsson H. Expression of c-kit and Ki 67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology 1999; 34: 416-24.
27. Berman J, O'Leary T. Gastrointestinal stromal tumors workshop. Human Pathol 2001, 32: 578-82.
28. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002 15; 20: 3898-905.
29. Sarlomo-Rikala M, El-Rifai W, Lahtinen T, Andersson LC, Miettinen M, Knuutila S. Different patterns of DNA copy number changes in gastrointestinal stromal tumors, leiomyomas, and schwannomas. Human Pathol 1998; 29: 476-81.
30. Nielsen TO, West RB, Linn SC, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002; 359: 1301-7.
31. Fédération nationale des centres de lutte contre le cancer. Standards, options et recommandations pour la prise en charge des sarcomes des tissus mous. John Libbey, Eurotext Paris 1995.
32. Matteo RP. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
33. Pierie JP. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-9.
34. Carson W, Karakousis C, Douglass H, Rao U, Palmer ML. Results of aggressive treatment of gastric sarcoma. Ann Surg Oncol 1994; 1: 244-51.
35. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-8.
36. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional dose doxorubicin plus ifosfamide versus high dose doxorubicin plus ifosfamide plus rh GM-CSF in advanced soft rissue sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2000; 18: 2676-84.
37. Edmonson J, Marks R, Buchner J, et al. Contrast of response to D-MAP + Sargamostim between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc Am Soc Clin Oncol 1999; 18 (abstr 2088).
38. Plaat BE, Holema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistant proteins. J Clin Oncol 2000; 18: 3211-20.
39. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002; 346: 683-93.
40. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1084-6
41. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
42. Druker BJ for the IRIS Study. Glivec vs IFN ARAC as initial therapy in patients with CML: results of a randomized study. Proc Am Soc Clin Oncol 2002; 21: 1a (abstract 1).
43. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor. N Eng J Med 2001, 344: 1052-56.
44. Ray-Coquard I, Le Cesne A, Blay JY. STI571 et tumeurs stromales digestives. Bull Cancer 2001; 88: 661-2.
45. Van Oosterom A, Judson I, Verwej J, et al. Update of the imatimib (STI 571, imatinib) phase I in gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 2002, 21 (abstract 327).
46. Van Oosterom A, Judson I, Verwej J, et al. Safety and efficacy of imatimib (STI-571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001, 358: 1421-3.
47. Von Mehren M, Blanke C, Joensuu H, et al. High incidence of durable responses induced by imatimib mesylate (imatinib) in patients with unresectable and metastatic gastrointestinal stromal tumors. Proc Am Soc Clin Onc 2002, 21 (abstract 1608).
48. Judson I, Verweij J, Van Oosterom A, et al. Imatimib (imatinib) an active agent for gastrointestinal stromal tumors but not for other soft tissue sarcoma subtypes not characterized for KIT and PDGR-R expression, results of EORTC phase II studies. Proc Am Soc Clin Onc 2002, 21 (abstract 1609).
49. Casali P, Verweij J, Zalcberg J, et al. Imatimib (imatinib) 400 vs 800 mg daily in patients with gastrointestinal stromal tumors: a randomized phase III trial from the EORTC Soft Tissue and Bone Sarcoma Group, the Italian sarcoma Group and the Australasian Gastro-intestinal Trials Group (ACITG): a toxicity report. Proc Am Soc Clin Onc 2002, 21 (abstract 1650).
50. Demetri G, Rankin C, Fletcher C, et al. Phase III dose-randomized study of Imatimib mesylate (Gleevec, STI-571) for GIST: intergroup S0033 early results. Proc Am Soc Clin Onc 2002, 21 (abstract 1651)
51. Van den Abbeele AD, Badawi RD, Cliche JP, et al. 18F-FDG-PET predicts response to imatimib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Onc 2002, 21 (abstract 1610).
52. Joensuu H, Krause A, Demetri G, et al. Gastrointestinal stromal tumor (GIST) patients who respond to imatimib (STI-571, Gleevec) show marked decline of circculatinng levels of VEGF, KIT, and bFGF in serum, but not stem cell factor levels. Proc Am Soc Clin Onc 2002, 21 (abstract 552).
53. Janicek MJ, Janicek MR, Merriam P, et al. Imaging responses to Imatimib mesylate (Gleevec, STI-571) in gastrointestinal stromal tumors (GIST): vascular perfusion patterns with Doppler ultrasound (DUS) and dynamic infrared imaging (DIRI). Proc Am Soc Clin Onc 2002; 21 (abstract 333).
54. Awan RA, Dixon RH, Antonescu CR, Maki RG. Patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans (DFS) may respond to Imatimib (STI-571, Gleevec). Proc Am Soc Clin Onc 2002, 21 (abstract 1637).
55. Hotfildet M, Lanvers C, Boos J, et al. C-kit-expressing Ewing tumor cells are insensitive to STI-571. Proc Am Soc Clin Onc 2002, 21 (abstract 1597).